サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1534079

卵巣がん治療薬の世界市場

Ovarian Cancer Drugs

出版日
ページ情報
英文 250 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
卵巣がん治療薬の世界市場
出版日: 2024年08月14日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 250 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

卵巣がん治療薬の世界市場は2030年までに48億米ドルに達する見込み

2023年に35億米ドルと推定される卵巣がん治療薬の世界市場は、分析期間2023-2030年にCAGR 4.6%で成長し、2030年には48億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである標的療法は、CAGR 5.5%を記録し、分析期間終了時には29億米ドルに達すると予測されます。ホルモン療法分野の成長率は、分析期間中CAGR 3.8％と推定されます。

米国市場は9億4,950万米ドルと推定、中国はCAGR 7.8％で成長予測

米国の卵巣がん治療薬市場は、2023年に9億4,950万米ドルと推定されます。世界第2位の経済大国である中国は、2023年から2030年にかけてCAGR 7.8%で推移し、2030年には市場規模9億9,130万米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.7%と4.9%と予測されています。欧州では、ドイツがCAGR 2.8%で成長すると予測されています。

世界の卵巣がん治療薬市場- 主要動向と促進要因のまとめ

卵巣がんは、一般的に診断が遅く、進行が複雑であるため、治療が最も困難な婦人科がんの1つです。卵巣がんの主な治療法には、手術、化学療法、標的療法、そして最近では免疫療法があります。パクリタキセルやカルボプラチンなどの薬剤を用いた従来の化学療法は、依然として治療の基本であり、残存がん細胞を除去するための外科的デバルキング後に行われることが多いです。これらの薬剤は効果的ではあるが、副作用が大きく、時間の経過とともに薬剤耐性を獲得する危険性があります。ベバシズマブ（血管新生阻害剤）やPARP阻害剤（オラパリブ、ニラパリブ、ルカパリブなど）といった薬剤が、卵巣がん治療における重要な進歩として登場しました。これらの治療法は、がん細胞のメカニズムを特異的に標的とするため、従来の化学療法と比較して、有効性と毒性の低減という点で利点があります。

標的治療の登場は、卵巣がん治療の展望を一変させました。特にPARP阻害剤は、BRCA1やBRCA2に変異のある患者や、相同組換え欠損症（HRD）の患者に顕著な効果を示しています。これらの薬剤は、がん細胞のDNA修復の弱点を突いて作用し、正常細胞を温存しながら細胞死に導く。一方、ベバシズマブは腫瘍に血液を供給する血管の成長を阻害し、がん細胞を効果的に飢餓状態にします。さらに、ペムブロリズマブのような薬剤が臨床試験で有望視され、免疫療法も進歩しています。このような進歩にもかかわらず、卵巣がんの治療は依然として複雑で、再発率が高いため、継続的な治療とモニタリングが必要です。より効果的で個別化された治療法を開発するために、この疾患の分子的・遺伝的背景を理解することに引き続き研究開発の焦点が当てられています。

卵巣がん治療薬市場の成長は、いくつかの要因によってもたらされます。認知度の向上と高度なスクリーニング技術による早期診断により、治療の対象となる患者層が拡大しています。ゲノミクスと分子生物学の技術的進歩により、より効果的で副作用の少ない標的療法や個別化医療の開発が促進されています。製薬企業による研究開発への多額の投資は、新薬や併用療法の充実したパイプラインにつながっています。また、希少がんや侵攻性がんをターゲットとする薬剤に対する規制上の優遇措置や迅速な承認プロセスも、市場の成長を後押ししています。さらに、世界の卵巣がん罹患率の上昇と高齢化が相まって、効果的な治療に対する需要が高まっています。学術機関、研究機関、製薬企業間の連携がイノベーションを促進し、研究の臨床応用を促進しています。こうした動向が進化を続ける中、卵巣がん治療薬市場は、より良い治療オプションへのニーズとがん治療の継続的な進歩に牽引され、大きな成長を遂げようとしています。

調査対象企業の例（全86件）

  • AbbVie, Inc.
  • Acrivon Therapeutics
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Co., Ltd.
  • F. Hoffmann-La Roche AG
  • GSK PLC
  • ImmunoGen, Inc.
  • Imvax
  • Merck & Co., Inc.
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Taiho Pharmaceutical Co., Ltd.
  • Vivesto AB
  • Zymeworks, Inc.;

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP26836

Global Ovarian Cancer Drugs Market to Reach US$4.8 Billion by 2030

The global market for Ovarian Cancer Drugs estimated at US$3.5 Billion in the year 2023, is expected to reach US$4.8 Billion by 2030, growing at a CAGR of 4.6% over the analysis period 2023-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$2.9 Billion by the end of the analysis period. Growth in the Hormonal Therapy segment is estimated at 3.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$949.5 Million While China is Forecast to Grow at 7.8% CAGR

The Ovarian Cancer Drugs market in the U.S. is estimated at US$949.5 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$991.3 Million by the year 2030 trailing a CAGR of 7.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 4.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.8% CAGR.

Global Ovarian Cancer Drugs Market - Key Trends and Drivers Summarized

Ovarian cancer is one of the most challenging gynecological cancers to treat due to its typically late diagnosis and the complexity of its progression. The primary treatment modalities for ovarian cancer include surgery, chemotherapy, targeted therapy, and, more recently, immunotherapy. Traditional chemotherapy, involving drugs such as paclitaxel and carboplatin, remains a cornerstone of treatment, often administered after surgical debulking to eliminate residual cancer cells. These drugs, while effective, come with significant side effects and the risk of developing drug resistance over time. Targeted therapies have emerged as a significant advancement in the treatment of ovarian cancer, with drugs like bevacizumab (an angiogenesis inhibitor) and PARP inhibitors (such as olaparib, niraparib, and rucaparib) offering more tailored approaches. These therapies specifically target cancer cell mechanisms, providing benefits in terms of efficacy and reduced toxicity compared to traditional chemotherapy.

The advent of targeted therapies has revolutionized the landscape of ovarian cancer treatment. PARP inhibitors, in particular, have shown remarkable success in patients with BRCA1 or BRCA2 mutations, as well as in those with homologous recombination deficiency (HRD). These drugs work by exploiting the DNA repair weaknesses in cancer cells, leading to cell death while sparing normal cells. Bevacizumab, on the other hand, inhibits the growth of blood vessels that supply the tumor, effectively starving the cancer cells. Additionally, immunotherapy is making strides with agents like pembrolizumab showing promise in clinical trials. Despite these advancements, the management of ovarian cancer remains complex, with a high recurrence rate necessitating ongoing treatment and monitoring. Research continues to focus on understanding the molecular and genetic underpinnings of the disease to develop more effective and personalized treatment options.

The growth in the ovarian cancer drugs market is driven by several factors. Increasing awareness and early diagnosis through advanced screening techniques are expanding the patient pool eligible for treatment. Technological advancements in genomics and molecular biology are facilitating the development of targeted therapies and personalized medicine, which are proving to be more effective and have fewer side effects. The substantial investment in research and development by pharmaceutical companies is leading to a robust pipeline of new drugs and combination therapies. Regulatory incentives and expedited approval processes for drugs targeting rare and aggressive cancers are also propelling market growth. Additionally, the rising incidence of ovarian cancer globally, coupled with an aging population, is increasing the demand for effective treatments. Collaborations between academic institutions, research organizations, and pharmaceutical companies are fostering innovation and expediting the translation of research into clinical practice. As these trends continue to evolve, the ovarian cancer drugs market is poised for significant growth, driven by the need for better therapeutic options and the ongoing advancements in cancer treatment.

Select Competitors (Total 86 Featured) -

  • AbbVie, Inc.
  • Acrivon Therapeutics
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Co., Ltd.
  • F. Hoffmann-La Roche AG
  • GSK PLC
  • ImmunoGen, Inc.
  • Imvax
  • Merck & Co., Inc.
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Taiho Pharmaceutical Co., Ltd.
  • Vivesto AB
  • Zymeworks, Inc.;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Ovarian Cancer Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Awareness and Early Diagnosis Expand Addressable Market Opportunity
    • Advances in Genomic and Molecular Biology Propel Development of Targeted Therapies
    • Rising Incidence of Ovarian Cancer Drives Demand for Effective Treatments
    • Development of Personalized Medicine Strengthens Business Case for Novel Therapies
    • Growing Adoption of PARP Inhibitors and Other Targeted Therapies Spurs Market Expansion
    • Integration of Immunotherapy in Treatment Protocols Throws Spotlight on Innovative Approaches
    • Expansion of Clinical Trials for Combination Therapies Drives Market Growth
    • Enhanced Screening Techniques and Diagnostic Tools Accelerate Early Detection
    • Rising Healthcare Expenditure and Improved Access to Treatments Expand Market Reach
    • Growing Focus on Reducing Side Effects and Improving Quality of Life Propels Demand for Advanced Therapies
    • Focus on Overcoming Drug Resistance Generates Opportunities for New Treatments
    • Market Penetration in Emerging Economies Propels Growth
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Ovarian Cancer Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Ovarian Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Ovarian Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Hormonal Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospital Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospital Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Hospital Pharmacies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Retail Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Retail Pharmacies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Online Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Online Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Online Pharmacies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Ovarian Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
  • JAPAN
    • Ovarian Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
  • CHINA
    • Ovarian Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
  • EUROPE
    • Ovarian Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Ovarian Cancer Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Ovarian Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
  • FRANCE
    • Ovarian Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
  • GERMANY
    • Ovarian Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Ovarian Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Ovarian Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Ovarian Cancer Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Ovarian Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Ovarian Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
  • INDIA
    • Ovarian Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: India 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: India 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Ovarian Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Ovarian Cancer Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Ovarian Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Ovarian Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Ovarian Cancer Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Ovarian Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030
  • AFRICA
    • Ovarian Cancer Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Ovarian Cancer Drugs by Therapy - Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Ovarian Cancer Drugs by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Hormonal Therapy, Chemotherapy and Radiation Therapy for the Years 2014, 2024 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Ovarian Cancer Drugs by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Ovarian Cancer Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2014, 2024 & 2030

IV. COMPETITION